Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Notes Payables: 2024-2025

Historic Notes Payables for ProPhase Labs (PRPH) over the last 2 years, with Sep 2025 value amounting to $3.2 million.

  • ProPhase Labs' Notes Payables rose 19.29% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 19.29%. This contributed to the annual value of $3.2 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, ProPhase Labs' Notes Payables stood at $3.2 million, which was up 31.34% from $2.4 million recorded in Q2 2025.
  • ProPhase Labs' 5-year Notes Payables high stood at $3.3 million for Q2 2024, and its period low was $2.4 million during Q1 2024.
  • For the 2-year period, ProPhase Labs' Notes Payables averaged around $2.8 million, with its median value being $2.7 million (2024).
  • Data for ProPhase Labs' Notes Payables shows a peak YoY increase of 19.29% (in 2025) and a maximum YoY decrease of 25.59% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows ProPhase Labs' Notes Payables stood at $3.2 million in 2024, then grew by 19.29% to $3.2 million in 2025.
  • Its Notes Payables stands at $3.2 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.5 million for Q1 2025.